{"product_id":"cdc25b-antibody-m-phase-inducer-phosphatase-2-bha17105399","title":"CDC25B Antibody \/ M-phase inducer phosphatase 2","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\u003cp\u003eCDC25B Antibody \/ M-phase inducer phosphatase 2 is a research-use-only Rabbit polyclonal (rabbit origin) Rabbit IgG directed against \u003cstrong\u003eCDC25B \/ M-phase inducer phosphatase 2\u003c\/strong\u003e. It is supplied for interpretation-focused detection and comparative profiling in WB, IHC, IF, FACS. Reported localization context: Cytoplasmic.\u003c\/p\u003e\n\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eTarget context:\u003c\/strong\u003e This antibody is raised against \u003cem\u003eAmino acids 119-248 of human CDC25B were used as the immunogen for the CDC25B antibody.\u003c\/em\u003e. Epitope context matters because isoforms, processing, and post-translational modifications can change what is accessible in a given assay.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Antigen affinity purified. Format influences background and compatibility with different detection chemistries; conjugated formats (when present) can simplify multiplexing and reduce reliance on secondary reagents.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpecies reactivity:\u003c\/strong\u003e Human, Mouse, Rat. Cross-species performance can vary with sequence divergence and epitope conservation, so interpretation should be anchored with appropriate biological controls.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLocalization:\u003c\/strong\u003e Cytoplasmic. Subcellular compartment context can help guide expectations in imaging assays and informs fractionation-based comparisons in lysate workflows.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eApplications:\u003c\/strong\u003e WB, IHC, IF, FACS. These indicate assay contexts where the antibody is commonly applied; actual performance depends on sample type and processing.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003ePolyclonal reagents can differ in how they recognize epitope features. Monoclonal antibodies often provide more consistent epitope targeting across lots, while polyclonal preparations may broaden recognition across related epitope variants. \u003c\/p\u003e\n\u003ch2\u003eBiological background\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eCDC25B \/ M-phase inducer phosphatase 2\u003c\/strong\u003e refers to the gene\/protein target stated in the product record. Protein targets can exhibit context-dependent expression, regulated turnover, isoform diversity, and post-translational modifications that affect apparent molecular weight and epitope accessibility. For curated functional annotation, sequence features, and expression context, consult \u003ca href=\"https:\/\/www.uniprot.org\/uniprotkb\/P30305\/entry\"\u003eUniProtKB P30305\u003c\/a\u003e, \u003ca href=\"https:\/\/www.ensembl.org\/\"\u003eEnsembl\u003c\/a\u003e, and \u003ca href=\"https:\/\/www.proteinatlas.org\/\"\u003eHuman Protein Atlas\u003c\/a\u003e.\u003c\/p\u003e\n\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eIntegrating antibody-based detection with single-cell and spatial atlasing efforts to connect RNA programs with protein-level abundance and localization in defined cell states.\u003c\/li\u003e\n\u003cli\u003eExpanding multiplexed imaging and high-content screening, where reagent specificity, cross-reactivity risk, and channel design (including direct conjugates) become central to interpretation.\u003c\/li\u003e\n\u003cli\u003eGrowing emphasis on reproducibility and application-specific validation frameworks (e.g., genetic perturbation controls, orthogonal measurements, and independent antibody strategies) when drawing mechanistic conclusions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon research applications\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eWestern blot (WB):\u003c\/strong\u003e commonly used to compare relative abundance\/size (e.g., band intensity or mobility shifts) between conditions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmunohistochemistry (IHC):\u003c\/strong\u003e commonly used to compare tissue- and cell-type–specific expression patterns in situ.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmunofluorescence (IF):\u003c\/strong\u003e commonly used to compare subcellular localization patterns and redistribution across stimuli or phenotypes.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFACS:\u003c\/strong\u003e commonly used for qualitative\/quantitative detection where compatible with the assay context.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eInterpretation typically focuses on relative differences (presence\/absence, fold-changes, compartment shifts, or population-level shifts) rather than absolute quantitation. When signal changes are observed, they may reflect altered expression, altered localization\/trafficking, changes in modification state, or differences in sample composition; orthogonal readouts and appropriate controls help distinguish these possibilities.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eApplication details (record-specific):\u003c\/strong\u003e Western blot: 0.5-1ug\/ml,Immunohistochemistry (FFPE): 2-5ug\/ml,Immunofluorescence: 5ug\/ml,Flow cytometry: 1-3ug\/million cells\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eApplication notes (record-specific):\u003c\/strong\u003e Optimal dilution of the CDC25B antibody should be determined by the researcher.\u003c\/p\u003e\n\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct description (record-specific):\u003c\/strong\u003e Central to the onset of mitosis in all eukaryotic cells is the CDC2 protein kinase, the activity of which is negatively regulated by phosphorylation and positively activated by dephosphorylation. The latter function is carried out by a specific phosphatase, CDC25. At least 3 human CDC25 genes code for the A, B, and C forms of CDC25. CDC25B is mapped to 20p13. P38 kinase has a critical role in the initiation of a G2 delay after ultraviolet radiation. Inhibition of p38 blocks the rapid initiation of this checkpoint in both human and murine cells after ultraviolet radiation. In vitro, p38 binds and phosphorylates CDC25B at serines 309 and 361, and CDC25C at serine-216; phosphorylation of these residues is required for binding to 14-3-3 proteins. In vivo, inhibition of p38 prevents both phosphorylation of CDC25B at serine-309 and 14-3-3 binding after ultraviolet radiation, and mutation of this site is sufficient to inhibit the checkpoint initiation. Regulation of CDC25B phosphorylation by p38 is a critical event for initiating the G2\/M checkpoint after ultraviolet radiation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePotential confounders:\u003c\/strong\u003e isoforms, proteolytic processing, and PTMs can change epitope presentation and apparent size; fixation\/denaturation state can also expose or mask epitopes. Species differences near the epitope may affect cross-reactivity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eControl concepts:\u003c\/strong\u003e include genetic perturbation (KO\/KD) or overexpression comparisons, orthogonal measurement (e.g., transcript or proteomics), and independent antibody\/epitope strategies. For conjugated reagents, include staining-only\/background controls appropriate to the detection chemistry.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eImmunogen\/epitope context is described as: \u003cem\u003eAmino acids 119-248 of human CDC25B were used as the immunogen for the CDC25B antibody.\u003c\/em\u003e. Monoclonal and polyclonal formats differ in epitope breadth; this can influence sensitivity to sequence variants, isoforms, or PTM-dependent recognition.\u003c\/p\u003e\n\u003c!-- Sources (internal):\n- UniProtKB entry P30305 (UniProt Consortium): https:\/\/www.uniprot.org\/uniprotkb\/P30305\/entry\n- Ensembl genome browser (EMBL-EBI \/ Wellcome Sanger): https:\/\/www.ensembl.org\/\n- The Human Protein Atlas (KTH \/ SciLifeLab): https:\/\/www.proteinatlas.org\/\n- A proposal for validation of antibodies (Uhlén et al., Nature Methods, 2016): https:\/\/www.nature.com\/articles\/nmeth.3995.pdf\n- Getting to reproducible antibodies: the rationale for sequenced recombinant characterized reagents (Bradbury \u0026 Plückthun, PEDS, 2015): https:\/\/academic.oup.com\/peds\/article\/28\/10\/303\/1478378\n- Standardize antibodies used in research (Bradbury, Plückthun et al., Nature, 2015): https:\/\/www.nature.com\/articles\/518027a.pdf\n--\u003e","brand":"NSJ Bioreagents","offers":[{"title":"0.5mg\/ml if reconstituted with 0.2ml sterile DI water \/ 100 ug","offer_id":53210341572973,"sku":"R32055","price":462.47,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/get_image_1dc9fd88-7e09-4915-b370-cea3bacf35c5.jpg?v=1775785679","url":"https:\/\/www.ebiohippo.com\/products\/cdc25b-antibody-m-phase-inducer-phosphatase-2-bha17105399","provider":"BioHippo","version":"1.0","type":"link"}